Zai Lab 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Zai Lab reported 3rd quarter 2026 total revenue of $108.2 million, with net product revenue up 2% sequentially and its China commercial business remaining profitable.
- R&D and SG&A expenses remained relatively stable compared with the prior year period, and cash was $659.7 million as of September 30th, 2026.
- In October, Zai Lab raised approximately $250 million in equity at no discount to market.
- In the global Phase 1 study of ZOSI plus atezolizumab, the confirmed objective response rate was 81.8% among 33 previously untreated efficacy-evaluable patients at the selected 1.6 milligrams per kilogram dose; estimated 6-month progression-free survival was 81.9% across all 33 patients.
- Among the first 15 patients, with a median follow-up of 10 months, median progression-free survival and median duration of response had not been reached; 10 of these 15 patients had not progressed at the data cutoff.
- Grade 3 or higher ZOSI-related adverse events occurred in 9.1% of patients in the 1.6 milligrams per kilogram doublet group, and there was a single case of grade 1 interstitial lung disease.
- Zai Lab completed enrollment in its Phase 1B/2 second-line EPNEC study and said preliminary results showed activity across a diversity of EPNEC subtypes.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for standing by and welcome to Zai Lab's third quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Christine Chiou, Senior Vice President of Investor Relations. Please go ahead. Thank you, operator.
Hello and welcome, everyone. Today's earnings call will be led by Dr. Samantha Du, Zai Lab's Founder, CEO, and Chairperson. She will be joined by Dr. Rafael Amado, President and Head of Global Research and Development, and Dr. Yajing Chen, Chief Financial Officer. Dr. Shan He, our Chief Business Officer, and Dr. Yizhe Wang, our Operating Partner, will also be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectations. These statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings. We will also refer to adjusted loss from operations, which is a non-GAAP financial measure.
Please refer to our earnings release furnished with the SEC on November 5, 2026, for additional information on this non-GAAP financial measure. At this time, it is my pleasure to turn the call over to Dr. Samantha Du.
Thanks, Christine. Good morning and good evening, everyone. We're entering one of the most important periods in Zai Lab's history. I founded Zai Lab to discover and develop innovative medicines for patients around the world. We have spent years building the talent, scientific capabilities, and infrastructure to make that possible. With zoci advancing toward a potential U.S. BLA submission next year, that vision is within our reach. Our first-line ESMO data strengthened our confidence that zoci can become the ADC backbone in small cell lung cancer. We are advancing the zoci-IO doublet into a global phase III study and building on it through our T-cell engager collaborations with Amgen and BI. The next two years are pivotal. By year-end, we expect three registrational studies underway across small cell lung cancer and neuroendocrine carcinomas.
In 2027, we anticipate two registrational results and our first potential U.S. BLA submission, positioning us for a U.S. launch as early as 2028. This would be a defining achievement for our company. Our recent $250 million financing further strengthens our ability to deliver on the plan. Our ambition extends well beyond zoci. Next week, we will present the first clinical data for ZL-1503, our internally developed bispecific for atopic dermatitis. We also expect three additional oncology and immunology assets in clinical development next year. Meanwhile, we continued to strengthen our China commercial business. Net product revenue grew 2% sequentially, and our China business remained profitable. This performance is consistent with the stabilization we outlined on our second quarter call. We remain on track with that trajectory and continue to expect a return to year-over-year product revenue growth in 2027.
I am very proud of what our team has accomplished, but our most important achievements are still ahead of us, and I look forward to updating you over the next year. With that, I will turn the call over to Rafael.
Thank you. Thank you, Samantha.
I will focus on our two lead programs, zoci and ZL-1503. Let me start with zoci, our potential first-in-class and best-in-class DLL3-targeting ADC. At ESMO, we presented first-line small cell lung cancer data from our global phase I study of zoci plus atezolizumab. Across 33 efficacy-evaluable previously untreated patients at the selected 1.6 milligrams per kilogram dose, the doublet achieved a confirmed objective response rate of 81.8%. Responses were rapid, with nearly all observed in the first tumor assessment. We are also seeing encouraging signs of durability. In all 33 patients, the estimated six-month progression-free survival was 81.9%. Among the first 15 patients who had a median follow-up of 10 months, median progression-free survival and median duration of response had not been reached. At the data cutoff, 10 of these 15 patients had not progressed. For context, chemo-IO has historically delivered a median PFS of roughly five months.
What further differentiates zoci is its potential to deliver this level of efficacy with substantially improved tolerability. With the 1.6 milligrams per kilogram doublet, grade 3 or higher zoci-related adverse events occurred in 9.1% of patients. There was a single case of grade 1 interstitial lung disease, which is consistent with our monotherapy experience. By comparison, grade 3 or higher treatment-related adverse events occur in roughly 60% or more of patients with chemo IO. We believe these results are unprecedented in first-line small cell lung cancer in an unselected patient population for platinum responsiveness. Together, this data challenged the conventional view of what an ADC-based regimen could achieve in first-line small cell lung cancer, both in terms of efficacy, durability, and tolerability. On the strength of this data, we are advancing zoci 1.6 milligrams per kilogram plus immunotherapy doublet into a global randomized phase III study.
We're also building on this backbone with T-cell engagers. The scientific rationale is complementary. Zoci rapidly reduces tumor burden, while the T-cell engager provides durable immune-mediated clearance. Importantly, zoci's favorable neurotoxicity profile may be particularly advantageous in these combinations, as T-cell engagers carry their own toxicity risk. Our global phase I-B study in small cell lung cancer with Amgen is moving rapidly, and our collaboration with BI is also advancing. Beyond first-line disease, our registrational phase III DLLEVATE study is evaluating zoci in second-line and later disease, including patients previously treated with tarlatamab. Contingent on enrolling sufficient post-tarlatamab, in addition to second-line patients, an interim analysis in 2027 could support a U.S. BLA submission for accelerated approval. Turning to extrapulmonary neuroendocrine carcinomas, or epNECs. This is an aggressive disease where there is no established standard of care beyond first-line chemotherapy.
Historical response rates are between 10%-20%, and median overall survival is about six months. We have completed enrollment in our phase I-B/II second-line epNEC study. Tomorrow, at the North American Neuroendocrine Tumor Society Conference, we will present preliminary results showing activity observed across a diversity of epNEC subtypes. Based on the totality of the clinical data thus far and feedback from FDA, we plan to pursue a potential accelerated approval supported by this single-arm study. We expect final results in 2027 and a potential submission that same year. Now turning to immunology and ZL-1503, our internally discovered long-acting IL-13/IL-31Rα bispecific antibody for atopic dermatitis. ZL-1503 is designed to address two major drivers of disease: IL-13-driven inflammation and IL-31-mediated itch. By simultaneously blocking both pathways, ZL-1503 has the potential to break the itch-scratch-inflammation cycle, providing more comprehensive disease control with a single biologic.
ZL-1503 also incorporates YTE modifications that extend its half-life, with the goal of enabling substantially less frequent dosing than currently available biologics. Next week, at the American College of Allergy, Asthma & Immunology meeting in Phoenix, we will present first-in-human data from the single ascending dose portion of our global phase I study in healthy volunteers. The SAD study has met its pre-specified endpoints, and we will share results demonstrating its safety profile, pharmacokinetics, immunogenicity, and sustained inhibition of IL-13 inflammatory pathway. Two more data sets follow next year. First, clinical efficacy, including itch control in patients with moderate to severe atopic dermatitis, and second, initial data from our fully enrolled IV to subcutaneous bridging study. We are planning phase II-B development in atopic dermatitis while also evaluating the potential for ZL-1503 across additional IL-13 and IL-31-mediated diseases. Our next wave of global assets continue to advance.
This includes ZL-6201, our LRRC15-targeted ADC, ZL-1311, our MUC17-targeting T-cell engager, and ZL-1222, our PD-1/IL-12 immunocytokine. Lastly, with our China regional pipeline, we continue to progress multiple regulatory and development opportunities, including potential additional filings for efgartigimod and the ongoing registrational development of elegrobart in thyroid eye disease. And with that, I'll hand it over to Yajing.
Thank you, Rafael. Our financial priorities are clear: return our China commercial business to growth, maintain our disciplined cost structure, and fund our highest-value global programs. Our third quarter results showed progress on all three. Total revenue was $108.2 million. Net product revenue increased 2% sequentially, reflecting continued stabilization of our China commercial business. Across our priority brands, ZEJULA held its competitive position despite ongoing volume-based pricing-related dynamics and a competitive PARP inhibitor landscape. VYVGART volumes continue to grow sequentially on new patient starts, and KarXT continued to gain traction ahead of potential NRDL inclusion next year. We expect a return to year-over-year product revenue growth in 2027, driven by continued demand across our priority brands and a new NRDL listing. At the same time, we have maintained strong discipline in managing our operating expenses.
Both R&D and SG&A expenses remained relatively stable compared with the prior year period, reflecting the operational efficiencies and resource optimization initiatives we have implemented across the organization. Our China commercial business remained profitable, providing a strong operating foundation as we continue investing in our global development program. We ended the quarter with a cash position of $659.7 million as of September 30th, 2026. In October, we raised approximately $250 million in equity at no discount to market, which further provides the financial flexibility to continue investing in the highest value opportunities. In summary, we have a profitable commercial business, a disciplined cost structure, and a balance sheet that supports our global innovative pipeline through its most important milestones. With that, I will open it up for questions.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
